Creative Medical shares surge 13.66% premarket on positive ADAPT trial data showing durable efficacy and safety for CELZ-201 in chronic back pain.

Creative Medical Technology Holdings (NASDAQ: CELZ) surged 13.66% in premarket trading following the release of positive interim data from its ADAPT clinical trial for CELZ-201 (Olastrocel). The trial demonstrated statistically significant improvements in functional disability (mean −15.3 percentage points) and pain reduction (mean −3.9 points) at 180 days, with 79% of patients achieving clinically meaningful outcomes. An independent Data Safety Monitoring Board confirmed no serious adverse events, reinforcing the therapy’s safety profile. The results position CELZ-201 as a potential non-surgical, disease-modifying treatment for chronic lower back pain, targeting a multi-billion-dollar market. The CEO emphasized this as a pivotal transition from clinical development to commercialization readiness, aligning with the stock’s sharp premarket rise.